Prenatal and postnatal steroid therapy and child neurodevelopment

Clinics in Perinatology

Volumn 31, Issue 3, 2004, Pages 529-544

  Friedman, Smadar ^a,b,c   Shinwell, Eric S ^a,c  

^a KAPLAN MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

ARTIFICIAL VENTILATION; BODY HEIGHT; BRAIN REGION; CEREBRAL PALSY; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DNA CONTENT; DRUG MEGADOSE; FETUS LUNG MATURATION; GESTATIONAL AGE; GROWTH DISORDER; HEAD CIRCUMFERENCE; HIGH RISK PREGNANCY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTESTINE PERFORATION; LUNG DEVELOPMENT; MEDICAL SOCIETY; MEDICAL SPECIALIST; MOLECULAR RECOGNITION; NEONATAL RESPIRATORY DISTRESS SYNDROME; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; ONTOGENY; POSTNATAL DEVELOPMENT; PRACTICE GUIDELINE; PREMATURE LABOR; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ADRENAL CORTEX HORMONES; ANIMALS; CHRONIC DISEASE; FEMALE; HUMANS; INFANT, NEWBORN; LUNG DISEASES; NERVOUS SYSTEM DISEASES; PRACTICE GUIDELINES; PREGNANCY; RISK FACTORS;

EID: 4344633722     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2004.04.016     Document Type: Review

References (112)

1. Crowley P. Prophylactic corticosteroids for preterm birth (Cochrane Review). The Cochrane library, issue 1. 2004;John Wiley & Sons, Chichester (UK)
2. Halliday H.L., Ehrenkrantz R.A., Doyle L.W. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. The Cochrane library. 2003;Update Software
3. Halliday H.L., Ehrenkrantz R.A., Doyle L.W. Moderately early postnatal (7-14 days) corticosteroids for preventing chronic lung disease in preterm infants. The Cochrane library. 2003;John Wiley and Sons Ltd., Chichester, UK
4. Halliday H.L., Ehrenkrantz R.A., Doyle L.W. Delayed (>3 weeks) corticosteroids for chronic lung disease in preterm infants. The Cochrane library. 2003;John Wiley and Sons Ltd., Chichester, UK
5. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA. 273:1995;413-418
6. Write L.L., Horbar J.D., Gunkel H., Verter J., Younes N., Andrews E.B., et al. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in low birth weight infants. Am J Obstet Gynecol. 173:1995;263-269
7. Crowley P.A. Antenatal corticosteroids therapy: a meta-analysis of the randomized trials 1972-1994. Am J Obstet Gynecol. 173:1995;322-335
8. Ment L., Oh W., Ehrenkranz R.A., Philip A.G., Duncan C.C., Makuch R.W. Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants. Am J Obstet Gynecol. 172:1995;795-800
9. Shanrakan S., Bauer C.R., Bain R., Write L., Zachary J. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in preterm infants. Am J Obstet Gynecol. 173:1995;305-312
10. Bertram C.E., Hanson M.A. Prenatal programming of postnatal endocrine responses by glucocorticoids. Reproduction. 124:2002;459-467
11. Yeung M.Y., Smyth J.P. Hormonal factors in the morbidities associated with extreme prematurity and the potential benefits of hormonal supplement. Biol Neonate. 81:2002;1-15
12. Jobe A.H., Newnham J., Willet K., Sly P., Ikegami M. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics. 102:1998;1116-1125
13. Matthews S.G. Antenatal glucocorticoids programming of the developing CNS. Pediatr Res. 47:2000;291-300
14. Rodriguez J.J., Montaron M.F., Petry K.G., Aurousseau C., Marinelli M., Premier S., et al. Complex regulation of the expression of the poly-sialyated form of neuronal cell adhesion molecule by glucocorticoids in the rat hippocampus. Eur J Neurosci. 10:1998;2994-3006
15. Challis J.R.G., Sloboda D., Matthews S.G., Holloway A., Alfaidy N., Howe D., et al. The fetal placental hypothalamic-pituitary-adrenal axis, parturition and postnatal health. Mol Cell Endocrinol. 185:2001;135-144
16. Ballard P.L., Ballard R. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol. 173:1995;254-262
17. Mesiano S., Jaffe R.B. Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev. 18:1997;378-403
18. Gluckman P.D., Sizonenko S.V., Basset N.S. The transition from fetus to neonate - an endocrine perspective. Acta Paediatr Suppl. 428:1999;7-11
19. Matthews S.G. Antenatal glucocorticoids and the developing brain: mechanisms of action. Semin Neonatol. 6:2001;309-317
20. Matthews S.G. Dynamic changes in glucocorticoid and mineralocorticoid receptor mRNA in the developing guinea pig brain. Brain Res. 107:1998;123-132
21. Matthews S.G., Challis J.R.G. Regulation of the hypothalamo-pituitary- adrenocortical axis in fetal sheep. Trends Endocrinol Metab. 7:1996;239-246
22. Carlos R.Q., Seidler F.J., Slotkin T.A. Fetal dexamethasone exposure alters macromolecular characteristics of rat brain development: a critical period for regionally selective alternations? Teratology. 46:1992;45-59
23. Brown R.W., Diaz R., Robson A.C., Kotelevfsev Y.V., Mullins J.J., Kaufman M.H., et al. The ontogeny of 11β-HSD2 and MR gene expression reveal intricate control of glucocorticoid action in development. Endocrinology. 137:1996;794-797
24. Seckl J.R. Glucocorticoids, feto-placental 11β-HSD2, and the early life origins of adult disease. Steroids. 62:1997;89-94
25. Benediktsson R., Calder A.A., Edwards C.R.W., Seckl J.R. Placental 11 β-hydroxysteroid dehydrogenase type 2 is the placental barrier to maternal glucocorticoids: ex vivo studies. Clin Endocrinol. 46:1997;161-166
26. Diaz R., Brown R.W., Seckl J.R. Distinct ontogeny of glucocorticoid and mineralocorticoid receptor and 11β-HSD type I and II mRNA in the fetal rat brain suggest a complex control of glucocorticoid actions. J Neurosci. 18:1998;2570-2580
27. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 8:1997;161-170
28. Slotkin T.A., Lappi S.E., McCook E.C., Tayyeb M.I., Eylers J.P., Seidler F.J. Glucocorticoids and the development of neuronal function: effects of prenatal dexamethasone exposure on central noradrenergic activity. Biol Neonate. 61:1992;326-336
29. Muneoka K., Mikuni M., Ogawa T., Kitera K., Kamei K., Takigawa M., et al. Prenatal dexamethasone exposure alters brain monoamine metabolism and adrenocortical responses in rat offspring. Am J Physiol. 273:1997;R1669-R1675
30. Slotkin T.A., Barnes G.A., McCook E.C., Seidler F.J. Programming of brainstem serotonin transporter development by prenatal glucocorticoids. Dev Brain Res. 93:1996;155-161
31. Levitt N.S., Lindsay R.S., Holmes M.C., Seckl J.R. Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology. 64:1996;412-418
32. Dean F., Yu C., Lingas R., Matthews S.G. Prenatal glucocorticoid modifies hypothalamo-pituitary-adrenal regulation in prepubertal guinea pigs. Neuroendocrinology. 73:2001;194-202
33. Bertram C., Trowern A.R., Whorwood C.B., Hanson M.A. Maternal protein restriction in utero results in altered glucocorticoid responses to the stress of weaning [abstract]. Pediatr Res. 50:2001;37
34. Kutzler M.A., Ruane E., Coksaygan T., Vincet S.E., Nathanielsz P.W. Effects of three courses of maternally administered dexamethasone at 0.7, 0.75, and 0.8 of gestation on prenatal and postnatal growth in sheep. Pediatrics. 113:2004;313-319
35. Haung W.L., Beazley L.D., Quinlivan J.A., Evans S.F., Newnham J.P., Dunlop S.A. Effects of corticosteroids on brain growth in fetal sheep. Obstet Gynecol. 94:1999;213-218
36. Uno H., Lohmiller L., Thieme C., Kemnitz J.W., Engle M.J., Roecker E.B., et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Dev Brain Res. 53:1990;157-167
37. Uno H., Eisele S., Sakai A., Shelton S., Baker E., Dejesus O., et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav. 28:1994;336-348
38. Dunlop S.A., Archer M.A., Quinlivan J.A., Beazley L.D., Newnham J.P. Repeated prenatal corticosteroids delay myelination in the ovine central nervous system. J Matern Fetal Med. 6:1997;309-313
39. Quinlivan J.A., Dunlop S.A., Newnham J.P., Evans S.F., Beazley L.D. Repeated, but not single, maternal administration of corticosteroids delays myelination in the brain of fetal sheep. Prenat Neonat Med. 4:1999;47-55
40. Huang W.L., Harper C.G., Evans S.F., Newnham J.P., Dunlop S.A. Repeated prenatal corticosteroid administration delays myelination of the corpus callosum in fetal sheep. Int J Dev Neurosci. 19:2001;415-425
41. Quinlivan J.A., Beazley L.D., Evans S.F., Newnham J.P., Dunlop S.A. Retinal maturation is delayed by repeated, but not single, maternal injections of betamethasone in sheep. Eye. 14:2000;93-98
42. Derks J.B., Mulder E.J.H., Visser G.H.A. The effects of maternal betamethasone administration on the fetus. Am J Obstet Gynecol. 102:1995;40-46
43. Mulder E.J.H., Derks J.B., Visser G.H.A. Antenatal corticosteroid therapy and fetal behavior: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynecol. 104:1997;1239-1247
44. Senat M.V., Minoui S., Multon O., Fernandez H., Frydman R., Ville Y. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomized study. Br J Obstet Gynecol. 105:1998;749-755
45. de Kloet E.R., Reul J.M., Sutanto W. Corticosteroids and the brain. J Steroid Biochem Mol Biol. 37:1990;387-394
46. Wright L.L., Verter J., Younes N., Stevenson D., Fanaroff A.A., Shankaran S., et al. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: the NICHD Neonatal Research Network. Am J Obstet Gynecol. 173:1995;269-274
47. Garland J.S., Buck R., Leviton A. Effect of maternal glucocorticoid exposure on risk of severe intraventricular hemorrhage in surfactant-treated preterm infants. J Pediatr. 126:1995;272-279
48. Leviton A., Dammann O., Allred E.N., Kuban K., Pagano M., Van Mar L., et al. Antenatal corticosteroids and cranial ultrasonographic abnormalities. Am J Obstet Gynecol. 181:1999;1007-1017
49. Canterino J.C., Verma U., Visintainer P.E., Elimian A., Klei S.A., Tejani N. Antenatal steroids and neonatal periventricular leukomalacia. Obstet Gynecol. 97:2001;135-139
50. Agarwal R., Chiswick M.L., Rimmer S., Taylor G.M., McNally R.J., Alston R.D., et al. Antenatal steroids are associated with a reduction in the incidence of cerebral white matter lesion in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 86:2002;F96-F101
51. Baud O., Foix-L'Helias L., Kaminski M., Audibert F., Jarreau P.H., Papiernik E., et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 341:1999;1190-1196
52. Baud O., Laudenbach V., Evrard P., Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res. 50:2001;706-711
53. Reist M., Marshall K.A., Jenner P., Halliwell B. Toxic effects of sulfite in combination with peroxy-nitrite on neuronal cells. J Neurochem. 71:1998;2431-2438
54. Doyle L.W., Ford G.W., Rickards A.L., Kelly E.A., Davis N.M., Callanan C., et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics. 106:2000;e2
55. Smolders-de Haas H., Neuvel J., Schmand B., Treffers P.E., Koppe J.G., Hoeks J. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10 to 12 year follow-up. Pediatrics. 86:1990;65-70
56. Schmand B., Neuvel J., Smmolders-de Haas H., Hoeks J., Koppe J.G. Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics. 86:1990;58-64
57. Dessesn A.B., Haas H.S., Koppe J.G. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics. 105:2000;e77
58. Liggins G.C., Howie R.N. A controlled trial of antepartum glucocorticoid treatment for prevention of respiratory distress syndrome in premature infants. Pediatrics. 50:1972;515-525
59. Wallace E.M., Chapman J., Stenson B., Wright S. Antenatal corticosteroid prescribing: setting standards of care. Br J Obstet Gynecol. 104:1997;1262-1266
60. Planer B.C., Ballard R.A., Ballard P.A., et al. Use of antenatal corticosteroids (ANCS) in USA [abstract]. Am J Obstet Gynecol. 175:1996;467A
61. Abbasi S., Hirsch D., Davis J., Tolosa J., Stouffer N., Debbs R., et al. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol. 182:2000;1243-1249
62. French N.P., Hagan R., Evans S.F., Godfrey M., Newnham J.P. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 180:1999;114-121
63. French N., Hagan R., Evans S., et al. Repeated antenatal corticosteroids (CS): behavior outcomes in regional population of very preterm (VP<33W) infants [abstract]. Pediatr Res. 43:1998;214
64. Thorp J.A., Etzenhouser J., O'Connor M., Belden B., Etzenhouser J., Hoffman E.L., et al. Effects of phenobarbital and multiple dose antenatal postnatal steroids on developmental outcome at age 7 years. Obstet Gynecol. 101:2003;363-373
65. Aghajafari F., Murphy K., Willan A., Ohlsson A., Amankwah K., Matthews S., et al. Multiple courses of antenatal corticosteroids: a systematic review and meta-analysis. Am J Obstet Gynecol. 185:2001;1073-1080
66. Guinn D.A., Atkinson M.W., Sillivan L., Lee M., MacGregor S., Parilla B.V., et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery. JAMA. 286:2001;1581-1587
67. Available at: www.npeu.ox.ac.uk/trials/protocol/teamspro.html.
68. Available at: actords@medicine.adelaide.edu.au.
69. Available at: www.utoronto.ca/macs.
70. Neonatal Institutes of Health Consensus Development Panel Antenatal corticosteroids revisited: repeated courses. NIH Consensus Development Conference Statement. August 17-18, 2000. Obstet Gynecol. 98:2001;144-150
71. Haddad H., Hsia D., Gellis S. Studies on respiratory rate in the newborn: its use in the evaluation of RDS in IDM. Pediatrics. 17:1956;204
72. Ewerbeck H., Helwig H. Treatment of idiopathic respiratory distress with large doses of corticoids. Pediatrics. 49:1972;467
73. Altman H. The respiratory distress syndrome of the newborn. S Afr Med J. 39:1965;746
74. Liggins G.C. Premature delivery of fetal lambs infused with glucocorticoids. J Endocrinol. 45:1969;515
75. Baden M., Bauer C.R., Colle E., Klein G., Taeusch H.W., Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 50:1972;526
76. Taeusch H.W., Wang N.S., Baden M., Bauer C.R., Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. II. Pathology. Pediatrics. 52:1973;850
77. Fitzhardinge P.M., Eisen A., Lejtenyi C., Metrakos K., Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics. 53:1974;877
78. Ogden B.E., Murphy S.A., Saunders G.C., Pathak D., Johnson J.D. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Respir Dis. 130:1984;817
79. Merritt T.A., Stuard I.D., Puccia J., Wood B., Edwards D.K., Finkelstein J., et al. Newborn tracheal aspirate cytology: classification during respiratory distress syndrome and bronchopulmonary dysplasia. J Pediatr. 98:1981;949
80. Durand M., Sardesai S., McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in preterm infants: a randomized controlled trial. Pediatrics. 95:1995;584-590
81. Shinwell E.S., Karplus M., Reich D., Weintraub Z., Blazer S., Bader D., et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 83:2000;F177-F181
82. O'Shea T.M., Kothadia J.M., Klinepeter K.L., Goldstein D.J., Jackson B.G., Weaver R.G., et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 104:1999;15
83. Yeh T.F., Lin Y.J., Huang C.C., Chen Y.J., Tsai W.F., Lien Y.J. Early postnatal (<12 hrs) dexamethasone therapy for prevention of BPD in preterm infants with RDS - a two year follow-up study. Pediatrics. 101:1998;e7
84. Stark A.R., Carlo W., Vohr B.R., Papile L., Bauer C., Donovan E., et al. National Institute of Child Health and Development Neonatal Research Network: adverse effects of early dexamethasone in extremely-low-birth-weight infants. N Engl J Med. 344:2001;95-101
85. American Academy of Pediatrics Committee on Fetus and Newborn Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 109:2002;330-338
86. Shinwell E.S., Karplus M., Bader D., Dollberg S., Gur I., Weintraub Z., et al. Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed. 88:2003;F36-F40
87. Jacobs H.C., Chapman R.L., Gross I. Premature conclusions on postnatal steroid effects. Pediatrics. 110:2002;200
88. Taylor C., Shah P., Dunn M. Meta-analysis of postnatal steroid use challenged. Pediatrics. 109:2002;716-717
89. Barrington K. Meta-analysis of postnatal steroid use challenged: reply to letter to the editor. Pediatrics. 109:2002;717
90. Ehrenkranz R.A., Mercurio M.R. Bronchopulmonary dysplasia. Sinclair J.C., Bracken M.B. Effective care of the newborn infant. 1992;399 Oxford University Press, New York
91. Bhuta T., Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 79:1998;F26-F33
92. Banks B.A. Postnatal dexamethasone for bronchopulmonary dysplasia: a systematic review and meta-analysis of 20 years of clinical trials. Neoreviews. 3:2002;c24-c34
93. Barrington K.J. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCT's BMC. Pediatrics. 1:2001;1
94. Yeh T.S., Lin Y.J., Lin H.C., Huang C.C., Hsieh W.S., Lin C.H., et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 350:2004;13
95. Flagel S.B., Vazquez D.M., Watson S.J., Neal C.R. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment and stress response. Am J Physiol Regul Integr Comp Physiol. 282:2002;R55-R63
96. Bloomfield F.H., Knight D.B., Breier B.H., Harding J.E. Growth restriction in dexamethasone-treated preterm infants may be mediated by reduced IGF-1 and IGFBP-3 plasma concentrations. Clin Endocrinol. 54:2001;235-242
97. Papile L.-A., Tyson J.E., Stoll B.J., et al. A multi-center trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 338:1998;1112-1118
98. Murphy B.P., Inder T.E., Huppi P.S., Warfield S., Zientara G.P., Kikinis R., et al. Impaired cerebral cortical grey matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 107:2001;217-221
99. Edwards A.D. Cerebral white matter damage in very preterm infants. Biol Neonate. 82:2002;292-293
100. Weichsel M.E. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurologic hazards. Ann Neurol. 2:1977;364
101. Vincedomini J.P., Nonneman A.J., DeKosky S.T., Scheff S.W. Perinatal glucocorticoids disrupt learning: a sexually-dimorphic response. Physiol Behav. 36:1986;145
102. Gould E. The effects of adrenal steroids and excitatory input on neuronal birth and survival. Ann N Y Acad Sci. 743:1994;73
103. Sysyn G.D., Petersson K.H., Patlak C.S., Sadowska G.B., Stonestreet B.S. Effects of postnatal dexamethasone on blood-brain barrier permeability and brain water content in newborn lambs. Am J Physiol Regl Integr Comp Physiol. 280:2001;R547-R553
104. Ferguson S.A., Holson R.R. Neonatal dexamethasone on day 7 causes mild hyperactivity and cerebellar stunting. Neurotoxicol Teratol. 21:1999;71
105. McGowan J.E., Sysyn G., Petersson K.H., Sadowska G.B., Mishra O.P., Delivoria-Papadopoulos M., et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci. 20:2000;7424-7429
106. Burch K., Rhine W., Baker R., Litman F., Kaempf J.W., Schwarz E., et al. Implementing potentially better practices to reduce lung injury in neonates. Pediatrics. 111:2003;e432-e436
107. Durand M., Mendoza M.E., Tantivit P., Kugelman A., McEvoy C. A randomized trial of moderately early low dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation and ventilation. Pediatrics. 109(2):2002;262-268
108. Watterberg K.L., Gerdes J.S., Gifford K.L., Lin H.M. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 104:1999;1258-1263
109. Decastro M.H., LaGamma E.F. Postnatal use of betamethasone (BETA) vs dexamethasone (DEX) for treatment of evolving BPD in extremely low birth weight (ELBW) neonates. Pediatr Res. 51:2002;356A
110. Lister P., Iles R., Shaw B., Ducharme F. Inhaled steroids for neonatal chronic lung disease (Cochrane Review). The Cochrane library, issue 2. 2002;Update Software, Oxford
111. Burchfield D.J. Postnatal steroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 111:2003;221
112. Blackmon L.R., Barrington K.J. Reply to Burchfield [letter]. Pediatrics. 111:2003;222